Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Mohan Pankaj
 2. Date of Event Requiring Statement (Month/Day/Year)
05/12/2016		 3. Issuer Name and Ticker or Trading Symbol
Oncobiologics, Inc. [ONS]
(Last)
(First)
(Middle)
C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President & CEO
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CRANBURY, NJ 08512		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 6,869,564
D
 
Common Stock 492,753
I
By Wife, Swati Mohan
Common Stock 21,739
I
By his child, Pankhuri Mohan
Common Stock 86,956
I
By 2015 Grantor Retained Annuity Trust of Swati Mohan
Restricted Stock Units (1) 405,797 (2) (3)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock   (4)   (5) Common Stock (6) $ 0 I By his child, Pankhuri Mohan

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Mohan Pankaj
C/O ONCOBIOLOGICS, INC.
7 CLARKE DRIVE
CRANBURY, NJ 08512		   X   X   President & CEO  

Signatures

/s/ Lawrence Kenyon, Attorney-in-Fact 05/12/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Granted pursuant to the Issuer's 2015 Equity Incentive Plan.
(2) Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock.
(3) The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering ("IPO"), subject to continued service through such event) and (b) time-based vesting restrictions (50% of the RSUs will satisfy the time-based vesting restrictions on each of the first and second anniversaries of December 31, 2015, subject to continued service through such dates). In addition, 100% of the RSUs will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event.
(4) N/A
(5) There is no expiration date.
(6) The reporting person beneficially owns 106 shares of Series A Preferred Stock. Such shares of Series A Preferred Stock will automatically convert into that number of shares of the Issuer's common stock immediately prior to the closing of the Issuer's IPO based on dividing the aggregate liquidation preference of $106,000 by the IPO price per share of common stock included in the units sold in the IPO.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.